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REVIEW
Experimental models and tools to tackle glioblastoma
Faye L. Robertson, Maria-Angeles Marqués-Torrejón, Gillian M. Morrison and Steven M. Pollard*
ABSTRACT
Glioblastoma multiforme (GBM) is one of the deadliest human
cancers. Despite increasing knowledge of the genetic and epigenetic
changes that underlie tumour initiation and growth, the prognosis for
GBM patients remains dismal. Genome analysis has failed to lead to
success in the clinic. Fresh approaches are needed that can stimulate
new discoveries across all levels: cell-intrinsic mechanisms
(transcriptional/epigenetic and metabolic), cell-cell signalling, niche
and microenvironment, systemic signals, immune regulation, and
tissue-level physical forces. GBMs are inherently extremely
challenging: tumour detection occurs too late, and cells infiltrate
widely, hiding in quiescent states behind the blood-brain barrier. The
complexity of the brain tissue also provides varied and complex
microenvironments that direct cancer cell fates. Phenotypic
heterogeneity is therefore superimposed onto pervasive genetic
heterogeneity. Despite this bleak outlook, there are reasons
for optimism. A myriad of complementary, and increasingly
sophisticated, experimental approaches can now be used across
the research pipeline, from simple reductionist models devised to
delineate molecular and cellular mechanisms, to complex animal
models required for preclinical testing of new therapeutic approaches.
No single model can cover the breadth of unresolved questions. This
Review therefore aims to guide investigators in choosing the right
model for their question. We also discuss the recent convergence of
two key technologies: human stem cell and cancer stem cell culture,
as well as CRISPR/Cas tools for precise genomemanipulations. New
functional genetic approaches in tailored models will likely fuel new
discoveries, new target identification and new therapeutic strategies
to tackle GBM.
KEY WORDS: Central nervous system, In vitro, CRISPR/Cas9,
Mouse, Human, Xenograft, GBM, Cancer, Brain tumour
“All models are wrong, but some are useful.” –
George E. P. Box.
The challenges of glioblastoma multiforme
Glioblastoma multiforme (GBM) is the most common malignant
primary brain tumour. Most cases arise sporadically. There are no
effective therapies, and multi-modality treatment with surgery,
radiotherapy and chemotherapy provides only ∼1 year median
survival (Stupp et al., 2005). Because GBMs often arise in young
adults and have poor prognosis, they account for more years of
active life lost than any other cancer (Burnet et al., 2005). Together
with medulloblastoma – the most common paediatric brain
tumour – GBMs therefore now account for more deaths in the
under 40s than any other cancer.
Gliomas are categorised as astrocytomas or oligodendrogliomas
based on the predominant cell type observed on histological
analysis. GBM, the most aggressive form of astrocytoma, is also,
unfortunately, the most common. Its defining features are abundant
mitotic cells, extensive necrosis, nuclear pleomorphism, and
hyperproliferation of endothelial cells (Louis et al., 2016).
A subset of patients harbour gain-of-function heterozygous
mutations in isocitrate dehydrogenase (IDH1/IDH2) (Parsons
et al., 2008). These IDH-mutant GBMs are the 5-10% of cases
previously termed secondary GBM (Louis et al., 2016).
In children, GBMs arising in the cerebral hemispheres are
often termed paediatric high-grade glioma (pHGG). When arising
within the midline/brainstem, they are termed diffuse intrinsic
pontine glioma (DIPG). Paediatric GBMs harbour different genetic
drivers than adult tumours (e.g. H3F3FA, encoding histone H3.3, is
mutated in pHGG and DIPG) (Mackay et al., 2017;
Schwartzentruber et al., 2012; Capper et al., 2018). Fortunately,
these paediatric and young-adult tumours are rare.
Why has it been so challenging to develop effective treatments
for GBM? There are many inherent challenges (Fig. 1): (1) GBMs
are often detected late and display extensive cellular and genetic
heterogeneity; (2) driver mutations occur at many levels within
canonical cell-growth and -survival pathways, undermining the
approach of ‘drugging’ a single oncogenic protein; (3) tumour cells
disperse widely in the brain parenchyma, limiting possibilities for
surgical resection; (4) tumour cells interact with diverse and
complex brain microenvironments (Quail and Joyce, 2017), often
existing in dormant or quiescent states that are resistant to cytotoxic
therapies (Chen et al., 2012a); (5) the blood-brain barrier (BBB)
limits drug bioavailability and facilitates immune evasion; and
(6) branched Darwinian evolution within the tumour creates diverse
subclonal variants that undermine targeted therapies and drive
relapse. Many other factors, including those related to how we
operate as a research community, have also hindered progress, with
barriers to progress across the whole research and clinical pipeline
(Aldape et al., 2019).
Here, we discuss the range of experimental models and tools that
can be deployed both to study the biology of GBM and to underpin
the search for new therapeutics. We summarise the contributions that
current models have made to our understanding of these tumours and
the avenues being explored to develop new therapies, focussing on
mammalian models. Non-mammalian models also clearly have value
in helping to dissect the key mechanisms and are summarised in
Box 1. We do not attempt to provide an exhaustive review of GBM
biology and preclinical studies; rather, we aim to present exemplars of
the available models and strategies, which increasingly can be
combined and readily deployed by individual labs.
We also look ahead to the many new and emerging tools. The
advent of CRISPR-based genome engineering, stem-cell-culture
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paradigms and high-content phenotypic screening are stimulating
new approaches to functional genetic dissection and drug discovery
efforts (O’Duibhir and Pollard, 2017). Few other human cancers
have such a wealth of tractable experimental models as GBM does.
These will now need to be exploited to drive new discoveries and
innovations in therapeutic strategies.
The need for tractable experimental models
The question of why we need models is perhaps self-evident:
to explore the fundamental biology and test therapeutics in a
way that is not possible by working directly with human patients.
It is perhaps useful to draw a distinction between two types of
experimental model: those designed from a reductionist viewpoint,
or alternatively those that embrace and try to recapitulate the ‘real’
disease complexity. Reductionist models provide a shortcut to
decisive mechanistic insights by focussing on specific aspects of
tumour biology (e.g. cells in culture as material for biochemical
studies), but thereby risk having limited disease relevance. An ideal
reductionist experimental model benefits from being as simple
as possible to ensure reliable mechanistic and functional insights;
these might often focus on one particular feature (e.g. in vitro
studies can provide new insights into cell cycle control, even though
host-tumour interactions or infiltration cannot be explored). By
contrast, when the goal is testing of therapeutic strategies, it often
becomes critical that models closely mimic the human disease
situation, with all the associated complexity. The more complex the
model, the less straightforward it will be to dissect clear
mechanisms because of increased heterogeneity and diversity of
signals, and a larger range of tumour cell states. Investigators
therefore need to balance the inevitable trade-offs in selecting a
model that best fits their research question.
Knowing your enemy: the molecular and cellular aetiology
of GBM
In order to model GBM effectively, we must understand both the
mutations and the epigenetic disruptions that lead to tumorigenesis
and engineer these into a disease-relevant cell of origin. GBM has
been extensively characterised using large-scale sequencing of its
exome, genome, transcriptome and epigenome (Brennan et al.,
2013; Cancer Genome Atlas Research Network, 2008; Capper et al.,
2018; Sturm et al., 2012; Verhaak et al., 2010). These and related
studies have revealed the simultaneous disruption of core cell cycle,
growth and survival pathways as major drivers of adult GBM.
Frequent gain-of-function mutations resulting from amplifications,
insertions/deletions or somatic activating point mutations are seen
for EGFR, MET and PDGFRA. These alterations stimulate the
downstream RAS/ERK and phosphoinositide-3-kinase (PI3K)/
AKT signalling pathways. Loss of the tumour suppressors
CDKN2A, TP53, RB, PTEN and NF1 is also frequently observed.
More recent work identified mutations in the TERT promoter across
the majority of GBMs (76% of IDH wild-type GBM cases) (Eckel-
Passow et al., 2015).
Epigenetic regulators – chromatin modifiers, remodellers, histone
variants and the DNAmethylation apparatus – are also a category of
frequently disrupted genes in adult and paediatric GBM (Brennan
et al., 2013). These were initially overlooked due to low-frequency
mutations across many individual genes that nevertheless disrupt


















Immune cells in the
surrounding microenvironment
Key
Fig. 1. Important challenges in
understanding the biologyof GBM.GBM
stem cells exist in various states (dormant/
quiescent, activated/quiescent or
proliferative) that are influenced by diverse
tumour microenvironments (TMEs).
Complex niches, immune interactions and
physical forces/mechanosignalling are all
poorly understood areas of GBM biology.
How these influence tumour cell signalling
circuits and the subsequent transcriptional
and epigenetic changes in GSC fate is
an area of active research. Targeting both
the quiescent and proliferative tumour
populations will be vital for any successful
therapeutic strategy.
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2013). Disruption of the core transcriptional and epigenetic
machinery therefore seems to be a general feature of GBMs
(Mack et al., 2015). GBMs also invariably display chromosome
instability, with whole-chromosome gains and losses, and are
therefore highly aneuploid with diverse and dynamic karyotypes.
GBM has a high degree of genetic heterogeneity, both within
and between tumours. Distinct oncogenes are amplified in a mosaic
and often mutually exclusive manner within a single tumour,
co-existing within intermingled subclonal populations (Snuderl
et al., 2011). This formidable level of heterogeneity has
inevitably hampered targeted therapies against these pathways.
Also, EGFR, as well as other oncogenic drivers (PDGFR and
MET), are often activated in different ways within the same tumour
(Furnari et al., 2015). Branched evolutionary processes further
contribute to the heterogeneity (Piccirillo et al., 2015), and so
interventions against key molecular targets may well need to be
focused on truncal mutations. Oncogene amplification often
takes the form of extrachromosomal DNA, which underlies rapid
shifts in copy number (Turner et al., 2017). Tumour cells
are therefore neither monoclonal nor monogenetic and exploit
strategies that enable rapid adaptation due to constant genomic
diversity – this is more akin to prokaryotic-like mechanisms
(Verhaak et al., 2019).
Researchers have also used transcriptional profiling to catalogue
the diversity of GBMs in an attempt to understand tumour
heterogeneity. This work led to the proposal of three tumour-cell-
intrinsic transcriptional signatures – classical, proneural and
mesenchymal – with a fourth previously reported ‘neural’ subtype
dismissed (Wang et al., 2017). However, single-cell analysis of
GBM specimens has shown that these subtypes are not mutually
exclusive, with cells from the same patients’ tumours expressing
distinct expression signatures (Patel et al., 2014). Therefore, instead
of thinking of these subtypes as discrete disease entities, it is
perhaps more helpful to view them as shifting developmental states,
with differentiation biases influenced by extrinsic or intrinsic cues.
Thus, while very valuable for exploring the biology of the disease,
transcriptional signatures are currently less valuable as clinical or
prognostic markers.
A major shift in our views of the aetiology of GBM resulted from
an improved understanding of the biology of neural development,
particularly the identity of neural stem cells (NSCs) and progenitor
cells. Many of the key markers that emerged in the 1990s, such as
nestin (Nes) (Lendahl et al., 1990), were found to be widely
expressed in gliomas (Dahlstrand et al., 1992). CD133 (Uchida
et al., 2000), a cell-surface epitope enriched in NSCs, was also used
in critical functional studies that isolated a subset of GBM cells with
enhanced tumour-initiation capacity compared to the CD133-
negative population (Singh et al., 2004). These findings support the
cancer-stem-cell model for GBM, with subsets of tumour cells
displaying NSC markers and these being more aggressive than
their more differentiated progeny. Recent studies, using in vivo
genetic-lineage tracing in xenografts, lend further support to a
differentiation hierarchy of GBM cells, and a subset of cells have
higher clonogenic output (Lan et al., 2017).
These discoveries raise the related question of whether
NSCs are a likely cell of origin (Chen et al., 2012b). Human
subventricular zone (SVZ) astrocytes with germinal activity
have been reported in the adult forebrain ventricles (Sanai et al.,
2004); however, whether NSCs persist into adulthood within the
human hippocampus remains controversial (Moreno-Jiménez et al.,
2019; Sorrells et al., 2018). Analysis of primary human GBM
specimens suggests that truncal driver mutations are indeed present
within the adult NSC niche – the SVZ – in many patients, in tissue
that is macroscopically normal (Lee et al., 2018). Several mouse
studies have also indicated that SVZ stem cells are more easily
transformed than astrocytes (discussed in the sections below).
Unfortunately, much confusion has arisen due to the fact that
differentiated astrocytes and endogenous adult NSCs (‘type B’
cells) share many markers, including GFAP (Doetsch et al.,
1999). Additionally, oligodendrocyte progenitor cells (OPCs),
glial precursors and astrocytes can also be transformed under
certain experimental conditions and are present in the SVZ.
Furthermore, it should be noted that there is not a single type of
NSC; this is a general term that encompasses diverse cell types with
different transcriptional and epigenetic profiles, spatial and
temporal identities, and associated differentiation biases (Obernier
and Alvarez-Buylla, 2019). How these distinct ‘flavours’ of an
NSC relate to the features of the resulting tumour or their
differentiation behaviour remains a major area of investigation.
Another consideration is the cell-cycle status. A continuum
of distinct cell-cycle states (dormant, primed quiescent, and
activated) have been found in single-cell analysis of the mouse
SVZ (Llorens-Bobadilla et al., 2015). However, the range of
quiescent states and their relationship to normal differentiation
programmes remains unknown.
Regardless of their origin, it is clear that GBM cells frequently
express a range of NSC markers, many of which also have key
functional roles: for example, neurodevelopmental transcription
factors (TFs), e.g. SOX, HOX, bHLH, ZF-TFs and FOX family
members. These have emerged as key effectors of the unconstrained
self-renewal of GBM stem cells (GSCs) that drives the disease
(Gallo et al., 2013; Bulstrode et al., 2017; Lu et al., 2016; Singh
et al., 2017; Suvà et al., 2014). Induction of their expression may be
one of the key outputs of the receptor tyrosine kinase signalling
Box 1. Non-mammalian models of glioblastoma
Non-mammalianmodels also provide great value in exploring glioblastoma,
although space constraints have limited our discussion here. The fly and
worm – Drosophila melanogaster and Caenorhabditis elegans – provide a
cost-effective alternative to mammalian studies that are easy to handle
and have an armoury of established and high-level genetic tools. These
have particular value for applications in unbiased genetic screens and
related clonal lineage analysis. Many molecular pathways are conserved
between Drosophila and human, and models of glioma have been
generated in Drosophila in which EGFR-Ras and PI3K pathways drive
neoplastic glial growths that are transplantable (Read et al., 2009).
Drosophila researchers have a long history of making key discoveries in
developmental neurobiology, particularly the mechanism of cell fate and
differentiation by neural stem and progenitor cells (Jacob et al., 2008;
Sousa-Nunes et al., 2010).
Zebrafish also provide unique opportunities for exploring GBM
(Pudelko et al., 2018). The transparency of the fish allows elegant
imaging studies, visualising tumour cell behaviours and host tissue
interactions, e.g. microglia–tumour-cell interactions (Hamilton et al.,
2016). Zebrafish is also an incredibly valuable vertebrate model for
performing forward genetic screens, and recent CRISPR tools
(Prykhozhij and Berman, 2018) are opening up possibilities for reverse
genetic approaches. In coming years, the ability to perform chemical and
genetic screens in zebrafish embryos and young adults in medium
throughput should complement the drug discovery efforts. It is
noteworthy that zebrafish is well suited for applications along the drug
discovery and development pipeline, particularly during the hit-to-lead
stages where assessing compound delivery, toxicities and target
specificity can all be rapidly and cheaply explored in a whole
vertebrate organism at scale (Stewart et al., 2014).
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pathways (Liu et al., 2015). Elevated activity of these master
regulatory and reprogramming factors may therefore explain the
limited terminal differentiation capacity of GSCs (Carén et al.,
2015). They may be locked into a perpetual cycle of self-renewal
(Bulstrode et al., 2017; Suva et al., 2013).
Comparison of single-cell profiling data suggests that GSCs have
transcriptional profiles similar to those of the outer SVZ/radial glia foetal
progenitors, which are a specific subset of amplifying progenitors in the
developing human cortex (Pollen et al., 2015; Patel et al., 2014).
Transcriptional resetting to afoetal-like statemay thereforebeafeatureof
GSCs. Stemness-associated neurodevelopmental pathways and
transcriptional/epigenetic programmes are therefore an area ripe
for identification of therapeutic targets, defining new biological
vulnerabilities that might not be uncovered through genome
sequencing alone (Mack et al., 2015).
GBM arises in the most complex organ in our bodies. The
elaborate tumour microenvironment (TME) influences tumour cell
fate in many ways. NSCs exist in a range of proliferative and non-
cycling/quiescent states (Patel et al., 2014), and local niches regulate
this balance (Hambardzumyan and Bergers, 2015). The acquisition
of a quiescent state by GSCsmay explain resistance to cytotoxic and
anti-mitotic agents (Bao et al., 2006; Chen et al., 2012a). The
vasculature in GBM forms a key niche that supports brain-tumour
stem-cell self-renewal (Gilbertson and Rich, 2007) and mediates
signals that impose a quiescent state (Ottone et al., 2014). The
vasculature in the tumour margin also comprises endothelial cells
with specialised tight junctions, pericytes and astrocyte processes;
this is a selective barrier, termed the blood-brain barrier (BBB). This
protects the brain, but limits delivery of drugs or biological
therapeutics to the infiltrative tumour cells. Although the BBB is
disrupted in the main tumour mass, cells within the infiltrative
margin, which is responsible for tumour regrowth, often infiltrate
widely into macroscopically normal surrounding tissue.
We still have a limited understanding of how themicroenvironment
shapes cell quiescence, proliferation, differentiation and infiltration.
Do subsets of cells in the tumour’s infiltrative margin harbour distinct
genetic or epigenetic disruptions (Piccirillo et al., 2015)? How can
they thrive and propagate in the absence of paracrine growth factors or
niche signals? Do they exist in different states when infiltrating via
endothelial versus white-matter routes? Is the balance of these fates
determined mainly by certain oncogenic drivers?
Immunotherapy with checkpoint inhibitors has not proven
straightforward for GBM, although encouraging results have been
reported recently (Ito et al., 2019). There is evidence for the
presence of T cells, macrophages and immune cytokines in the
GBM TME, and a glymphatic system exists – a peri-vascular
network dependent on glia with a pseudo-lymphatic function (Plog
and Nedergaard, 2018). Much research is also needed to understand
how this tumour immune microenvironment operates in the context
of GBM and how it can be exploited therapeutically.
In summary, GBM models must be suitable to study diverse
processes, including: neurodevelopmental transcriptional and
epigenetic programmes; the balance between dormancy,
quiescence, proliferation and differentiation; infiltration via
endothelial, white-matter or other routes; the BBB; immune
regulation; mechanosignalling; and responses to standard of care
(radio- and chemotherapy).
Current models encompass five major categories that we discuss
below: (1) GBM cell lines and primary cultures/explants (primary-
tumour derived); (2) in vitro engineered tumour-initiating cells
(e.g. transformed cultured NSCs); (3) ex vivo, brain/tumour slice
culture models; (4) in vivo mouse transplantation of tumour-
initiating cells; (5) genetically engineered mouse models
(GEMMs), often referred to as de novo, or autochthonous, models
(via breeding strategies and/or delivery of somatic mutations).
In vitro models: an abundance of choice
In vitro models are tractable and cost effective. They enable a
reductionist approach that is best suited to the dissection of cell-
intrinsic properties using biochemical, cell-biological and reverse-
genetics approaches. This views the cultured cells as autonomous
renegade cells, with features more akin to a microorganism in terms
of growth and self-sufficiency. Researchers can generate large
populations, which simplifies experimental approaches such as
chemical/genetic screens, transcriptomics and proteomics. Clonal
experiments or other single-cell analyses are straightforward,
providing rigorous information without the potentially confounding
complexity of diverse extrinsic signals. A major risk of working with
cultured cells is that they may diverge, genetically or epigenetically,
to the point of being non-relevant to the human disease. Thus, to
validate findings, careful consideration and controls must be in place
to ensure the disease relevance of any new findings, and in vitro
discoveries always need to be complemented with in vivo models.
There is a choice of working with established ‘classic’ cell lines
versus more recently developed patient-derived models grown in
NSC culture conditions. Widely used ‘classic’ cell lines, such
as U87MG, U251 and T98G, are grown in serum-supplemented
media, but these culture conditions promote astrocytic differentiation.
Inadvertently, investigators have therefore forced cells into a
differentiated astrocytic state, with transcriptional and epigenetic
programmes that do not reflect the neural stem/progenitor pathways
that underlie GSCs (Lee et al., 2006). The tumours that develop upon
xenotransplantation of such serum-grown cell lines do not resemble
GBM (Lee et al., 2006). This casts doubt on the value of any study
that has relied on these models. Furthermore, recent research has
shown that the U87MG cells distributed by ATCC – one of the most
popular cell lines (Pontén and Macintyre, 1968) – was in fact likely
switched with another cell line, as it does not match the original
Uppsala stocks (Allen et al., 2016). Although they are popular, our
view is that classic cell lines have limited utility, either for reductionist
mechanistic studies or for preclinical testing of agents. The field must
move away from these, as also advocated by Westermark et al. and
Xie et al. (Allen et al., 2016; Xie et al., 2015).
Primary-culture conditions to expand neural stem and progenitor
cells from the adult and developing CNS were first reported around
1990 (Temple, 1989; Reynolds and Weiss, 1992; Ray et al., 1993).
These studies described long-term culture of mouse NSCs from
both foetal brain tissue and from the adult SVZ using suspension
culture, as neurospheres (Reynolds and Weiss, 1992). The key
features of this approach were a lack of serum and presence of EGF
in the culture media.
Patient-derived primary GBM cells cultured under similar
conditions can be sustained long term, either in suspension or
adherent (on laminin) culture (Galli et al., 2004; Hemmati et al.,
2003; Pollard et al., 2009; Singh et al., 2003). These retain the
genetics and transcriptional state of the parental tumour, unlike the
serum-grown ‘classic’ cell lines (Lee et al., 2006). The GSCs that
emerge in these culture conditions also more faithfully recapitulate
the features of primary tumours when transplanted into rodent
brains, even after many passages. Thus, they provide a human,
disease-relevant, in vitromodel with stem-cell-like features. Genetic
disruptions in the parental tumour are well retained following long-
term culture, as well as within the resulting xenografts – including
the previously mentioned variable extrachromosomal elements
4


















carrying oncogenes (deCarvalho et al., 2018). Repositories of such
cells are now being developed to make these models accessible to
the research community (www.gcgr.org.uk; Xie et al., 2015). It is
important to reiterate that these cultures are established without any
genetic manipulations or cell sorting: the culture conditions
‘capture’ the GSC state, which enables experiments that
encompass some degree of genetic diversity of the original tumour.
NSCs and GSCs were originally expanded in suspension culture
as neurospheres. However, growth in suspension culture is not a
defining feature of stem cells and is not essential for their long-term
expansion (Conti et al., 2005; Sun et al., 2008). Working with cells in
adherent monolayers offers many experimental advantages, particularly
with regards to culture homogeneity, imaging approaches, clonal
propagation/picking, screening and quantitation (Conti et al., 2005),
thereby overcoming some inherent limitations of working with
suspension culture (Pastrana et al., 2011). Our own group and others
have also reported a much greater success in deriving new GBM
cell lines when using adherent culture, with >90% success for IDH
wild-type GBM (Pollard et al., 2009; Xie et al., 2015).
In 2014, Lancaster et al., building upon previous ES-cell self-
organisation studies of the Sasai lab (Kadoshima et al., 2013),
described a method for the generation of neural tissue from human
pluripotent stem cells (hPSCs) with some of the organised features
of the developing cortex (Lancaster et al., 2013). These have been
termed ‘organoids’ to highlight their similarities to existing
organoid systems defined for endodermal stem cell cultures, like
the use of Matrigel in suspension (Huch et al., 2017; Tuveson and
Clevers, 2019). Organoid culture paradigms enable the ex vivo
growth of primary GBM specimens to a large size (Hubert et al.,
2016). This allows modelling of the necrotic and hypoxic features of
human tumours, alongside the corresponding greater range of
quiescent, proliferative and differentiating cell states (Hubert et al.,
2016). However, generation of cerebral organoids is highly variable
and takes months of culture. Choosing between growing cells in an
adherent monolayer versus suspension culture, either as spheres or
organoids, is therefore influenced by whether working with purer
populations and homogeneity is essential (reductionist questions), or
whether researchers need the complexity and heterogeneity (necrosis,
quiescence/proliferation and differentiation) that is triggered in
suspension culture and is more reminiscent of the patient tumour.
In summary, GBM researchers are in the fortunate position of
being able to expand primary patient cells routinely from fresh
patient tumours, and classic cell lines are no longer required. Cells
can be grown as pure adherent cultures or in suspension or
organoid culture conditions to recreate more complex 3D models.
Normal neural stem and progenitor cells can also be isolated and
expanded in culture or generated from PSCs (i.e. iPSCs or
hESCs). Arguably, for no other human cancer are we in such a
favourable position in the choice and flexibility of mouse and
human in vitro models.
Engineering GBM in vitro
GSCs display many features of foetal NSCs, such as many of the
molecular markers that are expressed within a specific progenitor
cell termed the outer SVZ radial glia (Pollen et al., 2015). Human
foetal NSCs can be easily derived, and retain a diploid karyotype
and differentiation capacity over multiple passages (Sun et al.,
2008). Comparison of GSCs to ‘normal’, non-malignant human
foetal NSCs has provided insights into the differential molecular
programmes underlying acquisition of the malignant phenotype.
Adherent human NSCs can also be obtained via in vitro
differentiation of hPSCs (Conti et al., 2005), although primary
human foetal NSCs arguably provide a more reliable starting source
for comparison to GBM.
NSCs can be expanded in vitro and differentiated into astroglial
and oligodendrocyte progeny. These NSCs, and perhaps also their
immature precursor-cell descendants, are a likely cell of origin for
GBM and can be readily genetically manipulated in culture. An
obvious experimental strategy is therefore to model GBM by
engineering driver mutations stepwise and in combinations in vitro
and subsequently transplant the cells in vivo (see below).
A range of standard molecular biology approaches have been
used to deliver oncogenes and short hairpin RNAs (shRNAs),
including plasmid transfection and lentiviral or retroviral
transduction. Bachoo et al. showed that postnatal primary cortical
astrocytes and NSCs from cdkn2a (encoding Ink4a and ARF)-null
mice can be transformed in vitro using retrovirus to induce
constitutive expression of the GBM-associated oncogenic protein
EGFRvIII (Bachoo et al., 2002). The transduced primary cortical
astrocytes and NSCs formed tumours when transplanted into the
brains of immunocompromised mice.
NSCs derived from differentiating PSCs have also been
transformed into glioma-initiating cells. Funato et al. derived
neural progenitor cells from human ESCs to model DIPG in vitro
and to study the effects of the histone H3.3K27M mutation on
cellular growth kinetics and tumorigenicity (Funato et al., 2014).
They used lentiviral transduction to introduce activated PDGFRA
and wild-type or mutant H3.3 along with an shRNA against TP53.
Instead of viral transduction, researchers can also use transposases
(e.g. the PiggyBac system) for stable random integration of
oncogene expression cassettes (Ding et al., 2005).
Precision engineering: genome editing with CRISPR
The emergence of CRISPR/Cas9 technology has transformed many
areas of biology, including cancer research (Hsu et al., 2014; Wright
et al., 2016). Genome editing with CRISPR/Cas9 now enables not
only genetic knockout of tumour suppressors (preferred over RNAi-
mediated knockdown), but also a range of more complex and
precise genetic changes such as knock-ins or engineering of
complex alleles (Fig. 2). These CRISPR-based techniques have also
opened up possibilities for new genetic screening approaches, both
in vitro (Toledo et al., 2015) and in vivo (Chow et al., 2017), and,
importantly, allow researchers to generate isogenic cell line pairs for
precisely controlled experimentation.
CRISPR/Cas9-induced cuts to genomic DNA can be repaired by
cellular mechanisms that result in efficient gene disruption with
knockouts via formation of insertion/deletion mutations. They can
also be repaired by homologous recombination combined with gene
targeting to introduce specific point mutations or more sophisticated
modifications, such as the knock-in of epitope tags, protein fusions
or reporters (Dewari et al., 2018). Bressan et al. demonstrated
that CRISPR/Cas9-mediated gene targeting by homologous
recombination is efficient in mouse and human NSCs (Bressan
et al., 2017). In the coming years, we will see them deployed for
lineage tracing (CreERT2 knock-in), label-retaining assays for
quiescence (H2B-GFP pulse-chase experiments), conditional alleles
(loxP or frt-based recombination), knock-in of degrons [e.g SMAsh-
tag (Chung et al., 2015)] and engineering of more complex
chromosomal structural changes (Choi and Meyerson, 2014).
Recently, independent groups have used CRISPR/Cas9
technology in human organoid culture systems to engineer
oncogene constructs or disrupt tumour suppressors such as the
TP53 locus (Bian et al., 2018; Ogawa et al., 2018). Cells isolated
from these organoid tumours bear the molecular signature of
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mesenchymal GBM samples, express markers of heterogeneous cell
types and can be transplanted into mice, where they form tumours
(Ogawa et al., 2018).
Such isogenic panels of engineered transformed cells and their
parental controls provide the critical models that can improve target
identification and validation in drug discovery efforts. This
overcomes the obstacle of genetic variation in mechanistic studies.
Rigorous functional genetic studies probe the genes and pathways
regulating key facets of GBM biology and can address some of the
common pitfalls in preclinical cancer-target validation studies
(Kaelin, 2017).
In vivo modelling: transplantation and genetically
engineered models
Despite their many advantages, in vitro cellular models have limited
scope for exploration of extrinsic signals regulating GBM stem-cell
fate, such as tumour-host interactions and immune control. Ex vivo
modelling approaches include organotypic brain slice cultures.
These are useful for bridging the gap between in vitro cell culture
studies and the in vivo animal studies, and have been extensively
used in neuroscience to explore neuronal electrical activity
(Humpel, 2015). Slice culture methods offer opportunities for
imaging and tracking cell responses with great precision over
microanatomical location in the correct brain-tissue architecture,
such as GBM cell interactions with the SVZ niche (Marqués-
Torrejón et al., 2017). However, whole-animal models undoubtedly
provide the key disease-relevant models for GBM.
Mice are by far the most experimentally accessible mammalian
model. This is primarily due to their ease of genetic manipulation,
short breeding times, and shared organ systems and physiology.
Transplantation of tumour-initiating cells into mice provides a
relatively low-cost model for the rapid interrogation of tumour
biology and for identifying therapeutic vulnerabilities. These can be
either transformed/engineered cells, or cancer cells from primary
tumours. However, the downside is the disruption of tumour tissue
architecture and potential selection events that occur within
the transplantation procedure, and so these approaches are
complemented by autochthonous models in which de novo
tumours are formed by using genetic approaches. Mutations can
be either introduced via the germ line and breeding strategies, or
through somatic cell mutation (Fig. 3). These complementary
strategies for studying tumours in vivo (Fig. 4) are discussed in
detail below.
Transplantation of tumour-initiating cells
Transplants can be allografts, in which the implanted cancer cells
are from the same species as the recipient, e.g. mouse into mouse, or
xenografts, where implanted cells are from a different species, e.g.
human into mouse. The resulting grafts can be orthotopic – i.e.
transplanted intracranially, typically into the brain with stereotactic
surgery – or heterotopic, most typically subcutaneous. The former is
clearly more attractive, as it provides the correct tissue/organ
context. Subcutaneous injection has been widely used because it is
easy technically and therefore enables larger throughput, but cannot
be used to explore brain infiltrative behaviour and lacks appropriate
brain microenvironments (Liu et al., 2015). Subcutaneous
transplants are hence undesirable; investigators should avoid
using this approach if possible.
An advantage of orthotopic xenografts is the precise control of
spatial and temporal tumour initiation. Large cohorts of tumour-
bearing mice can therefore be generated with consistent tumour
sizes and sites. Monitoring of the transplanted tumour cells using
bioluminescence in vivo, which requires stable expression of a
luciferase cassette in the transplanted cells, is now widely used and
enables longitudinal tracking of tumour growth. The downsides are
that this approach typically requires large numbers of cells for
injection, and there is limited ability to control events during
engraftment and seeding steps. Also, the injection procedure itself
inevitably creates an injury, thereby disrupting normal tissue
architecture and physiology.
Transplantation into syngeneic hosts has the advantage of












Fig. 2. Sources of GBM tumour cells and their
capture in vitro. Tumour tissue and tumour cell
populations can be obtained from rodent models
(see Fig. 3) or patients (adult or paediatric).
Tumour-initiating cells can be maintained in
culture using neural-stem-cell culture conditions
(serum-free media with growth factors EGF and
FGF2). These can be expanded in suspension
as spheres or organoids, or in an adherent
monolayer. Clonal cell lines can be obtained,
and cells plated in microtiter plates for arrayed
genetic or chemical screens. Cells and tumour
explants can also be engrafted on brain slice
cultures to model tumour-host interactions.
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generated from carcinogen-induced rodent gliomas or from
transgenic mice, cultured, and transplanted into syngeneic hosts.
This approach was used to generate the GL261 cell line, which is
often used for immune studies (Akbasak et al., 1991). However,
GL261 has genetically drifted and does not model an authentic
GBM-like tumour (Szatmári et al., 2006). Histologically they do not
match GBM, and they have accrued mutations, such as in KRAS, a
mutant allele that is not associated with GBM. With the advent of
CRISPR technology, as discussed above, researchers can achieve
specific genetic alterations through stepwise engineering of adult
mouse NSCs, rendering them tumorigenic when orthotopically
transplanted into the brains of isogenic mice with a fully functional
immune system. So, a new range of models will soon emerge,
enabling studies of GBM immune regulation.
Human cell lines or patient-derived cells require transplantation
into immunocompromised mice to prevent immune rejection. Direct
implantation of freshly isolated tumour cells or tissue fragments,
without intervening cell culture steps, has been used to create
patient-derived orthotopic xenograft (PDOX) models. This has the
advantage of capturing genetic diversity, as well as aspects of the
TME, e.g. vessels, the extracellular matrix and likely some immune
regulators, providing the most direct attempt to capture disease-
relevant features of the tumours without any in vitro selection.
Maintenance of PDOX models is costly and labour intensive,
limiting access to a few institutions. These models also cannot
sidestep the inherent problem of selection and drift that inevitably
occurs as the tumours are propagated through mice – both for
distinct subpopulations of tumour cells and for the loss of human
TME as murine stroma takes over. Ben-David and colleagues
assessed copy number alterations (CNAs) in patient-derived
xenografts from multiple cancer types across serial in vivo
passages and found a striking rates of CNA (Ben-David et al.,
2017). So, in prolonged in vivo culture, direct patient xenografts
may actually perform no better than GSC cultures expanded in vitro
prior to transplantation (deCarvalho et al., 2018). GSCs have the
advantage that cells can be fully characterised, archived and
distributed to the community.
Genetically engineered mouse models: germ-line and somatic
mutation
Before the sophisticated modern tools of molecular biology
emerged, researchers used chemical mutagenesis, e.g. with N-
ethyl-nitrosurea (ENU), to develop glioma models (Schiffer et al.,
1978). Such tumours harbour mutations found in human GBM,
display genetic heterogeneity, and arise within a disease-relevant
microenvironment in an immunocompetent host. However, the
efficiency and reproducibility of tumour formation is low.
Polyclonal origins and lack of control of the specific genetic
drivers are also an issue. For these reasons, GEMMs have become
the favoured option.
GEMMs are created by introducing defined genetic alterations in
the germline and using breeding strategies that generate compound
mutants with alterations in both oncogenes and tumour suppressors.
Such autochthonous models can provide valuable insights into early
initiation events. Inevitably, mutations in some of the relevant genes
are early lethal and therefore must be engineered using conditional
TV TV









Knock-in (LOF promoter reporter)
Knock-in protein reporter
Knock-in (promoter reporter)
Knock-in protein epitope tag
Transcriptional activation
Transcriptional repression
Fig. 3. Engineering NSCs and GSCs with CRISPR-based
genome editing. A variety of different genetic or epigenetic
manipulations can be introduced using CRISPR/Cas-assisted
gene engineering, either mutations (bottom left) or knock-in
alleles (bottom right). ex1/2, exon 1/2; NSC, neural stem cell;
GSC, glioblastoma stem cell; eGSC, engineered glioblastoma
stem cell; GFP, green fluorescent protein; LOF, loss of function;
TV, targeting vector.
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approaches (e.g. Cre-loxP recombination strategies). CreERT2
driver alleles result in tissue-restricted and temporally controlled
tumour-suppressor deletion through Cre recombinase induction
with tamoxifen.
A key mouse breeding model for primary GBM was reported by
the Parada group by combining Trp53 loss and conditional loss of
Nf1 (Zhu et al., 2005). This important study demonstrated the
functional importance ofNf1 loss in driving malignant astrocytoma.
In fact, this preceded the realisation thatNf1 loss is a recurrent driver
in GBMs (Cancer Genome Atlas Research Network, 2008). Using
this fully penetrant mouse model and combining it with various Cre
drivers, this group has been able to explore, using elegant mouse
genetics, the candidate cell of origin for GBM (Alcantara Llaguno
et al., 2015, 2016, 2009, 2019) and the importance of the quiescent
GBM stem-cell-like population in driving relapse (Chen et al.,
2012a). NG2-CreER mice demonstrated that the proneural subtype
was likely derived from OPCs, whereas other GBM subtypes
resembled tumours generated in Nes-CreER mice, suggesting a
CNS progenitor cell of origin (Alcantara Llaguno et al., 2015).
Similar studies using autochothonous models and de novo
tumour formation also suggested a lower barrier to malignant
transformation in the NSCs than in astrocytes (Chow et al., 2011).
For IDH-mutant GBM, Bardella et al. used conditional expression
of the IDH1R132H allele in the adult SVZ to model the early events
of gliomagenesis (Bardella et al., 2016).
A related approach is to initiate tumours by delivery of a Cre-
expressing virus, thus spatially restricting mutations to specific
brain regions (e.g. cortex or SVZ). This has provided evidence that,
following ablation of the key tumour suppressors Rb, Trp53 or Pten,
SVZ NSCs are more easily transformed than parenchymal
differentiated astrocytes (Jacques et al., 2010).
Viral delivery can also be used to introduce GBM oncogenes
in vivo. A lentivirus-based delivery system for HRas and AKT
overexpression also indicated that cells within the NSC-containing
regions were more easily transformed than cells in other brain
regions (Marumoto et al., 2009). A popular approach has been the
RCAS-TVA system. Cells producing TVA, the receptor for
subgroup A avian leukosis viruses, are susceptible to infection
with replication-competent avian sarcoma-leukosis virus long
terminal repeat with splice acceptor (RCAS) viral vectors. RCAS-
TVA has contributed to our understanding of the potential cell(s) of
origin of GBM (Holland et al., 2000). Holland et al. developed
transgenic mouse lines expressing the TVA in Nes- or Gfap-
expressing cells, presumed to be progenitor cells and differentiated
astrocytes, respectively, and bred these withCdkn2a-knockout mice
(Holland et al., 1998). Nes-TVA mice were more susceptible to
tumour formation than Gfap-TVA (Holland et al., 2000). However,
endogenous human and mouse NSCs with self-renewal and
differentiation capacity also express GFAP (Doetsch et al., 1999),
and so this marker alone does not distinguish differentiated astrocyte
populations. Jiang et al. also used RCAS with lineage-restricted
promoters and confirmed a significant impact of differentiation state
on tumour aggressiveness, with more restricted progenitors being less
malignant (Jiang et al., 2017). Recent research demonstrated the
utility of combining CRISPR/Cas9, as this system can deliver
oncogenes and/or also induce loss-of-function mutations in tumour
suppressors (Oldrini et al., 2018). A limitation of the RCAS-TVA
system is the need to breed specific TVA-expressing mouse strains.
Moreover, there are viral cargo limitations (maximum 2.5 kb), which
poses some restriction (e.g. the EGFRvIII oncogene is 2.8 kb long).
A further constraint of all of autochthonous models – either
those developed via breeding or somatic mutation – is the
X
AdultPostnatalFoetal




















Fig. 4. In vivomousemodels can be generated through
transplantation of cells or tumour tissues, or through
engineered driver mutations (by breeding or somatic
mutation). (Top panel) Shown are foetal, postnatal and
adult brain injections of either tumour explants, cells,
CRISPR ribonucleoproteins, plasmids or viral vectors
(viral delivery of genetic material). Bottom panel: in vivo
mousemodels can also be generated by breeding animals
that carry germline mutations.
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possibility for polyclonal tumour initiation. For the models
generated by the Parada group (discussed above; Chen et al.,
2012a), this was indeed an issue, as survival data were
complicated by the emergence of spontaneous tumours in the
hindbrain. So, although providing a useful tool to generate
highly penetrant autochthonous tumours, this approach is likely
to become superseded by CRISPR- and PiggyBac-based
approaches that can deliver combinations of oncogenes and
tumour suppressors in multiplex, directly in vivo, and with
high enough efficiency for tumour formation (Pathania et al.,
2017). These plasmid-based approaches do not require mouse
breeding or virus production, and enable the delivery of larger
cargo sizes.
Future prospects
What are the potential improvements in GBM models in coming
years? The lack of a human immune system is a limitation for patient-
derived xenografts. Given the importance of cancer immunotherapy
in the clinic, immunocompetent models are urgently needed to
understand how to overcome the immunosuppressive mechanisms in
GBM. Strategies to develop mice with a humanised immune system
are emerging (Billerbeck et al., 2011;Mahne et al., 2017; Shultz et al.,
2012).
CRISPR-based approaches could be used to engineer multiplex
inducible GBM drivers in human NSCs, which could then be
engrafted into a foetal mouse brain, enabling the generation of a
de novo chimeric tumour. Also, with improvements in iPSC
culture and differentiation protocols, it will become possible to
produce homogeneous populations of isogenic primary human
cells (e.g. microglia, macrophages and endothelial cells). These
could be studied in co-culture with tumour cells in vitro or
following transplantation to explore host-tumour cell interactions.
iPSC technology combined with genome editing can therefore
create complex ex vivo models that will likely be helpful in the
triage of compounds in small-molecule drug discovery
programmes.
Advances in genome editing technologies now mean that, to
some extent, all animals have the potential to become genetically
manipulable, and in the future this will drive a new range of large
animal models to complement and support mouse and human
studies. Immunocompromised strains of the Yucatan minipig have
been used as a host for human-cell-line xenografts (Khoshnevis
et al., 2017). The size and gyrencephalic structure of the porcine
brain, along with a BBB physiology similar to that in humans,
makes it a more comparable model to the human brain than
are rodent brains. Dogs also provide a useful model of GBM as the
disease arises in them spontaneously, generating, in an
immunocompetent host, similar heterogeneous infiltrative
tumours to those found in humans (Koehler et al., 2018).
Preclinical testing of new therapeutics – whether small
molecule, biologics, or gene or cell therapy – should therefore
have a much greater quality and diversity of available models. This
will underpin better-quality clinical trials based upon strong
scientific evidence. It is also clear that testing of new therapeutics
in models needs to incorporate the current standard of care to
ensure therapies are tested in a manner that will closely relate to
existing clinical care and clinical trials design; i.e. treating the
mouse in ‘mouse hospitals’ with surgical debulking, radiotherapy
(using small-animal radiation research platforms) and
temozolomide regimes. This will be expensive and logistically
challenging; even more so when one considers that these control
tests would ideally be performed in large animal models.
Conclusions
Our knowledge of the origins and molecular programmes
underpinning GBM has steadily expanded. GBMs are driven by
simultaneous disruptions to ‘classic’ cancer signalling pathways
that operate in the context of a neural stem or progenitor cell state.
These mutated pathways cannot easily be blocked or reversed with
targeted therapies due to pathway redundancy and extensive intra-
tumoural heterogeneity. New approaches will be needed that
focus on functional studies and deep understanding of the tumour
biology. No single approach will suffice. Fortunately for GBM, we
are witnessing the emergence of a range of high-quality and
complementary mammalian and human models. The community
will need to share these and associated tools to stimulate a new era of
greater cross-collaboration between the fundamental research,
translational and drug discovery effort, and clinical studies. We
are optimistic that the long-awaited new discoveries, new validated
targets and new therapeutic strategies will emerge.
Acknowledgements
The authors thank Val Brunton and Noor Gammoh for helpful comments on the
manuscript.
Competing interests
The authors declare no competing or financial interests.
Funding
S.M.P. is supported by a Cancer Research UK Senior Research Fellowship
(A19778) and The Brain Tumour Charity Quest for Cures Collaborative Team Award
(GN-000358). S.M.P. and G.M.M. are supported by Cancer Research UK Centre
Accelerator Grant [A21992; The Glioma Cellular Genetics Resource (www.gcgr.org.
uk)]. F.L.R. is supported by the Edinburgh Cancer Research UK Centre, Clinical
Research Fellowship.
References
Akbasak, A., Oldfield, E. H. and Saris, S. C. (1991). Expression and modulation of
major histocompatibility antigens on murine primary brain tumor in vitro.
J. Neurosurg. 75, 922-929. doi:10.3171/jns.1991.75.6.0922
Alcantara Llaguno, S., Chen, J., Kwon, C.-H., Jackson, E. L., Li, Y., Burns, D. K.,
Alvarez-Buylla, A. and Parada, L. F. (2009). Malignant astrocytomas originate
from neural stem/progenitor cells in a somatic tumor suppressor mouse model.
Cancer Cell 15, 45-56. doi:10.1016/j.ccr.2008.12.006
Alcantara Llaguno, S. R., Wang, Z., Sun, D., Chen, J., Xu, J., Kim, E., Hatanpaa,
K. J., Raisanen, J. M., Burns, D. K., Johnson, J. E. et al. (2015). Adult lineage-
restricted CNS progenitors specify distinct glioblastoma subtypes.Cancer Cell 28,
429-440. doi:10.1016/j.ccell.2015.09.007
Alcantara Llaguno, S. R., Xie, X. and Parada, L. F. (2016). Cell of origin and cancer
stem cells in tumor suppressor mouse models of glioblastoma. Cold Spring Harb.
Symp. Quant. Biol. 81, 31-36. doi:10.1101/sqb.2016.81.030973
Alcantara Llaguno, S., Sun, D., Pedraza, A. M., Vera, E., Wang, Z., Burns, D. K.
and Parada, L. F. (2019). Cell-of-origin susceptibility to glioblastoma formation
declines with neural lineage restriction. Nat. Neurosci. 353, 811. doi:10.1038/
s41593-018-0333-8
Aldape, K., Brindle, K. M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M. R.,
Gottardo, N., Gutmann, D. H., Hargrave, D., Holland, E. C. et al. (2019).
Challenges to curing primary brain tumours. Nat. Rev. Clin. Oncol. 16, 509-520.
doi:10.1038/s41571-019-0177-5
Allen, M., Bjerke, M., Edlund, H., Nelander, S. andWestermark, B. (2016). Origin
of the U87MG glioma cell line: Good news and bad news. Sci. Transl. Med. 8,
354re3. doi:10.1126/scitranslmed.aaf6853
Bachoo, R. M., Maher, E. A., Ligon, K. L., Sharpless, N. E., Chan, S. S., You,
M. J., Tang, Y., DeFrances, J., Stover, E., Weissleder, R. et al. (2002).
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms
governing terminal differentiation and transformation along the neural stem cell
to astrocyte axis. Cancer Cell 1, 269-277. doi:10.1016/S1535-6108(02)00046-6
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst,
M. W., Bigner, D. D. and Rich, J. N. (2006). Glioma stem cells promote
radioresistance by preferential activation of the DNA damage response. Nature
444, 756-760. doi:10.1038/nature05236
Bardella, C., Al-Dalahmah, O., Krell, D., Brazauskas, P., Al-Qahtani, K.,
Tomkova, M., Adam, J., Serres, S., Lockstone, H., Freeman-Mills, L. et al.
(2016). Expression of Idh1(R132H) in the murine subventricular zone stem cell
niche recapitulates features of early gliomagenesis. Cancer Cell 30, 578-594.
doi:10.1016/j.ccell.2016.08.017
9


















Ben-David, U., Ha, G., Tseng, Y.-Y., Greenwald, N. F., Oh, C., Shih, J.,
McFarland, J. M., Wong, B., Boehm, J. S., Beroukhim, R. et al. (2017). Patient-
derived xenografts undergo mouse-specific tumor evolution. Nat. Genet. 49,
1567-1575. doi:10.1038/ng.3967
Bian, S., Repic, M., Guo, Z., Kavirayani, A., Burkard, T., Bagley, J. A.,
Krauditsch, C. and Knoblich, J. A. (2018). Genetically engineered cerebral
organoids model brain tumor formation. Nature Publishing Group 15, 631-639.
doi:10.1038/s41592-018-0070-7
Billerbeck, E., Barry, W. T., Mu, K., Dorner, M., Rice, C. M. and Ploss, A. (2011).
Development of human CD4+FoxP3+ regulatory T cells in human stem cell
factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-
3-expressing NOD-SCID IL2Rγ(null) humanized mice. Blood 117, 3076-3086.
doi:10.1182/blood-2010-08-301507
Brennan, C.W., Brennan, C.W., Verhaak, R. G.W., Verhaak, R. G.W., McKenna,
A., Campos, B., Campos, B., Noushmehr, H., Noushmehr, H., Salama, S. R.
et al. (2013). The somatic genomic landscape of glioblastoma. Cell 155, 462-477.
doi:10.1016/j.cell.2013.09.034
Bressan, R., Dewari, P., Kalantzaki, M., Gangoso, E., Matjusaitis, M., Garcia-
Diaz, C., Blin, C., Grant, V., Bulstrode, H., Gogolok, S. et al. (2017). Efficient
CRISPR/Cas9-assisted gene targeting enables rapid and precise genetic
manipulation of mammalian neural stem cells. Development 144, 635-648.
doi:10.1242/dev.140855
Bulstrode, H., Johnstone, E., Marqués-Torrejón, M. Á., Ferguson, K. M.,
Bressan, R. B., Blin, C., Grant, V., Gogolok, S., Gangoso, E., Gagrica, S. et al.
(2017). Elevated FOXG1 and SOX2 in glioblastoma enforces neural stem cell
identity through transcriptional control of cell cycle and epigenetic regulators.
Genes Dev. 31, 757-773. doi:10.1101/gad.293027.116
Burnet, N. G., Jefferies, S. J., Benson, R. J., Hunt, D. P. and Treasure, F. P.
(2005). Years of life lost (YLL) from cancer is an important measure of population
burden–and should be considered when allocating research funds. Br. J. Cancer
92, 241-245. doi:10.1038/sj.bjc.6602321
Cancer Genome Atlas Research Network. (2008). Comprehensive genomic
characterization defines human glioblastoma genes and core pathways. Nature
455, 1061-1068. doi:10.1038/nature07385
Capper, D., Jones, D. T. W., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D.,
Koelsche, C., Sahm, F., Chavez, L., Reuss,D. E. et al. (2018). DNAmethylation-
based classification of central nervous system tumours. Nature 555, 469-474.
doi:10.1038/nature26000
Carén, H., Stricker, S. H., Bulstrode, H., Gagrica, S., Johnstone, E., Bartlett,
T. E., Feber, A., Wilson, G., Teschendorff, A. E., Bertone, P. et al. (2015).
Glioblastoma stem cells respond to differentiation cues but fail to undergo
commitment and terminal cell-cycle arrest. Stem Cell Rep. 5, 829-842. doi:10.
1016/j.stemcr.2015.09.014
Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G. and Parada,
L. F. (2012a). A restricted cell population propagates glioblastoma growth after
chemotherapy. Nature 488, 522-526. doi:10.1038/nature11287
Chen, J., McKay, R. M. and Parada, L. F. (2012b). Malignant glioma: lessons from
genomics, mouse models, and stem cells. Cell 149, 36-47. doi:10.1016/j.cell.
2012.03.009
Choi, P. S. and Meyerson, M. (2014). Targeted genomic rearrangements using
CRISPR/Cas technology. Nat. Commun. 5, 3728. doi:10.1038/ncomms4728
Chow, L. M. L., Endersby, R., Zhu, X., Rankin, S., Qu, C., Zhang, J., Broniscer,
A., Ellison, D. W. and Baker, S. J. (2011). Cooperativity within and among Pten,
p53, and Rb pathways induces high-grade astrocytoma in adult brain.Cancer Cell
19, 305-316. doi:10.1016/j.ccr.2011.01.039
Chow, R. D., Guzman, C. D., Wang, G., Schmidt, F., Youngblood, M. W., Ye, L.,
Errami, Y., Dong, M. B., Martinez, M. A., Zhang, S. et al. (2017). AAV-mediated
direct in vivo CRISPR screen identifies functional suppressors in glioblastoma.
Nat. Neurosci. 20, 1329-1341. doi:10.1038/nn.4620
Chung, H. K., Jacobs, C. L., Huo, Y., Yang, J., Krumm, S. A., Plemper, R. K.,
Tsien, R. Y. and Lin, M. Z. (2015). Tunable and reversible drug control of protein
production via a self-excising degron. Nat. Chem. Biol. 11, 713-720. doi:10.1038/
nchembio.1869
Conti, L., Pollard, S. M., Gorba, T., Reitano, E., Toselli, M., Biella, G., Sun, Y.,
Sanzone, S., Ying, Q.-L., Cattaneo, E. et al. (2005). Niche-independent
symmetrical self-renewal of a mammalian tissue stem cell. PLoS Biol. 3, e283.
doi:10.1371/journal.pbio.0030283
Dahlstrand, J., Collins, V. P. and Lendahl, U. (1992). Expression of the class VI
intermediate filament nestin in human central nervous system tumors. Cancer
Res. 52, 5334-5341.
deCarvalho, A. C., Kim, H., Poisson, L. M., Winn, M. E., Mueller, C., Cherba, D.,
Koeman, J., Seth, S., Protopopov, A., Felicella, M. et al. (2018). Discordant
inheritance of chromosomal and extrachromosomal DNA elements contributes to
dynamic disease evolution in glioblastoma.Nat. Genet. 50, 708-717. doi:10.1038/
s41588-018-0105-0
Dewari, P. S., Southgate, B., Mccarten, K., Monogarov, G., O’Duibhir, E., Quinn,
N., Tyrer, A., Leitner, M.-C., Plumb, C., Kalantzaki, M. et al. (2018). An efficient
and scalable pipeline for epitope tagging in mammalian stem cells using Cas9
ribonucleoprotein. eLife 7, 87. doi:10.7554/eLife.35069
Ding, S., Wu, X., Li, G., Han, M., Zhuang, Y. and Xu, T. (2005). Efficient
transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell
122, 473-483. doi:10.1016/j.cell.2005.07.013
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Moreno-Jiménez, E. P., Flor-Garcıá, M., Terreros-Roncal, J., Rábano, A., Cafini,
F., Pallas-Bazarra, N., Ávila, J. and Llorens-Martıń, M. (2019). Adult
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